Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer

Pharmacoeconomics. 2007;25(3):181-5. doi: 10.2165/00019053-200725030-00001.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Cost-Benefit Analysis
  • Decision Making*
  • Humans
  • Neoplasm Staging
  • Receptor, ErbB-2 / analysis
  • Reimbursement Mechanisms / economics*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab